Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 ...

Osteogenesis imperfecta (OI) refers to a group of rare genetic bone disorders that results in the formation of fragile bones.

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 ...

Try Now>> See the top stocks recommended by analysts >> Read More on MREO:Disclaimer & DisclosureReport an Issue Mereo BioPharma’s Setrusumab Study: A Potential Breakthrough for Osteogenesis ...

Osteogenesis imperfecta (OI) refers to a group of bone disorders in which certain genetic mutations affect the formation of ...

Jorden Borders, 35, of Minnesota, tortured her children to make them seem sick — and ended up falsely claiming $18,000 in ...

Mereo BioPharma Group plc (NASDAQ:MREO) is one of the Best 52-Week Low Penny Stocks to Buy Now. On July 9, Mereo BioPharma ...

A mother will spend decades in prison after she was sentenced for the torture of her three children, including forcing them to fake illnesses.

While tributes pour in for South Africa’s female leaders this Women’s Month, thousands of women with disabilities remain marginalised, battling discrimination, inaccessibility, and a job market that ...

GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

A child maltreatment investigation began in 2022 after Children’s Minnesota hospital in the Twin Cities treated one of the ...

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.